Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet (London, England)(2018)
Abstract
Galapagos and Gilead Sciences.
MoreTranslated text
Key words
active psoriatic arthritis,psoriatic arthritis,selective janus kinase,filgotinib,placebo-controlled
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined